Julie Bruneau



Principaux champs de recherche
Chercheur(e)s associé(e)s
Organisations associées

Aucune organisation partenaire n’a été touvée.

Projets de recherche récents

CRISM-Quebec-Maritimes: Research on interventions in drug misuse

2014/15-2020/21 • $2,374,845 • PI,CO,Other
Substance misuse remains a significant global public health problem which carries a heavy burden for abusers and their families alike. This disorder is indeed associated with suffering and severe health problems in patients, distress among family members, as well as tremendous costs to society....

Feast Centre for Indigenous STBBI Research

2019/20-2020/21 • $1,646,473 • PI,CO,Other
The current political and social realities of Indigenous life in Canada (i.e., higher rates of sexually-transmitted and blood-borne infections (STBBIs), ongoing colonization, the need for health policy and programs responsive to Indigenous world views, etc.) requires thoughtful attention to...

Achieving hepatitis C elimination in Canada; addressing the needs of the diverse groups at risk

2018/19-2020/21 • $1,238,848 • PI,CO
Hospitalizations, deaths and costs from hepatitis C are increasing in Canada due to undiagnosed and untreated cases. Hepatitis C virus infections can cause chronic infection of the liver that is silent for 20-30 years before about a fifth of infected people develop liver failure or liver cancer....

CRISM Urgent Guideline Activities Related to COVID-19

2020/21 • $1,000,000 • PI
Aucun sommaire

Integrating community-based recruitment with data linkage to inform and enhance scale-up of hepatitis C treatment among people who inject drugs: A pan-Canadian 'virtual' cohort study

2019/20-2020/21 • $367,486 • PI,CO
Roughly 250,000 Canadians live with chronic hepatitis C virus (HCV) infection, a major cause of liver cirrhosis, cancer, and transplantation that places a significant burden on infected individuals and the health system. People who inject drugs (PWID) are the principal group at risk of this...

Evaluation of supervised consumption services in Montreal in the context of COVID-19

2020/21 • $249,900 • PI,CO,Other
Supervised consumption services (SCS) aim to reduce the harms of injection drug use by providing a controlled environment for people to inject drugs, with emergency response in the event of an overdose, sterile injection supplies, drug checking, counseling, referrals, and other supports. The...

2020/21 • $200,000 • PI
Aucun sommaire

Signatures of protective immunity against HCV

2020/21 • $139,740 • PI,CO
Hepatitis C virus (HCV) infection is still a public health priority as many remain undiagnosed and increased infections in association with the opioid epidemic. Direct acting antivirals offer complete cure in >95% of infected individuals but do not prevent reinfection. Furthermore, HCV...

Chronic non-cancer pain, substance use, and related harms: Towards an optimal treatment pathway for people who inject drugs in the context of the opioid crisis

2020/21 • $100,000 • PI,CO
One in five Canadians lives with chronic pain, an invisible but debilitating, distressing, and costly condition that is complex and difficult to treat. Meanwhile, from January 2016 to June 2019, 13,900 opioid-related deaths were recorded in Canada, with contamination of the illicit drug supply a...

Characterizing mortality rates and associated modifiable determinants among people who inject drugs in a large, urban Canadian city: Implications for future population health interventions

2019/20-2020/21 • $77,301 • PI,CO
People who inject drugs (PWID) often face profound socio-economic disadvantage and are one of the most vulnerable groups in society, with a global mortality rate nearly 15 times that of the general population. Largely concentrated in cities, PWID are disproportionately exposed to housing...

Rapid review of the impacts of "Big Events" on people who use drugs and delivery of harm reduction and drug treatment services: Implications for strengthening systems in response to COVID-19

2020/21 • $50,000 • PI,CO,Other
"Big Events" are significant disruptions (e.g. natural disasters) that create social instability and increase vulnerability to drug-related harms. The COVID-19 pandemic has the potential for significant short- and long-term impacts on risks and harms for people who use drugs, and harm reduction...

The National CIHR Hepatitis C Network (NCHCN)

2015/16-2019/20 • $4,520,000 • PI,CO,Other
Hepatitis C virus (HCV) infection is a global health problem. In Canada, it is estimated that 242,500 individuals are infected with the incidence of approximately 4,000 new cases per year. The majority of newly infected individuals develop persistent infection and chronic liver disease over many...

The complex dynamics of mental health and risk among people who inject drugs: implications for HIV and hepatitis C transmission

2014/15-2019/20 • $1,513,392 • PI,CO
The transmission of HIV and hepatitis C (HCV) contributes substantially to the morbidity and mortality caused by substance use disorders. Injection drug use is one of the main drivers of these two epidemics worldwide. The reasons why persons who inject drugs (PWID) engage in behaviours that put...

Understanding the treatment benefits of novel antiviral agents for hepatitis C: quality of life, health utility, cost, and return to work

2016/17-2019/20 • $470,169 • PI,CO
Hepatitis C virus (HCV) has been identified as having the highest health burden of any infectious disease pathogen. Direct-acting antiviral agents (DAAs) are new drugs that offer the promise of cure and substantially improved tolerability. Because of the expense of these DAAs, and the large...

Harnessing the Quebec Pain Registry and the Quebec health administrative databases to improve the management of chronic non-cancer pain in women and men

2017/18-2019/20 • $200,000 • PI,CO,Other
Chronic non-cancer pain (CNCP) affects 1/5 Canadians and its human and economical burdens are enormous. CNCP is poorly managed, with medications such as opioids being one of few tools available to family doctors who do not have easy access to multidisciplinary teams. Nonetheless, little good...

Dissecting Protective Immunity during Multiple Episodes of HCV Infection

2014/15-2018/19 • $887,823 • PI,CO
Development of vaccines against many viral infections is hindered by our limited understanding of what constitutes an efficient and protective immune response and what parameters can be used to evaluate the success of vaccine candidates. Hepatitis C virus (HCV) infection is transmitted through...

Examining the impact of contacts with healthcare and harm-reduction services on the injection trajectories of people who inject drugs

2016/17-2018/19 • $105,000 • Scholarship/Fellowship,Other
People who inject drugs (PWID) are at high risk of infection with hepatitis C virus (HCV) and human immunodeficiency virus (HCV). Previous research has suggested that the injection patterns of these individuals evolve differently over time, with some injecting persistently at high, moderate and...

A multidisciplinary multimodal in-hospital intervention to reduce the risk of prolonged opioid therapy after surgery: A randomized control trial

2018/19 • $100,000 • PI,CO,Other
Most patients who undergo surgery are being prescribed opioids, primarily in efforts to minimize acute and chronic postsurgical pain. But for some patients, the use of opioids continue months after surgery. Previous work from our team has identified risk factors for the prolonged use of opioids...

Signatures of protective immunity against HCV

2018/19 • $100,000 • PI,CO
Hepatitis C virus (HCV) infection remains a public health priority as many remain undiagnosed worldwide with increased rates of new infections in association with the opioid epidemic. The broad use of novel direct acting antivirals (DAAs) that offers complete cure in >95% of infected individuals...

Cannabidiol as a new intervention for cocaine dependence

2014/15-2017/18 • $449,788 • PI,CO
This study seeks to determine whether capsules of cannabidiol (CBD) will decrease the desire to use cocaine among dependent individuals during early abstinence, as well as the risk of relapse after detoxification. A growing concern in public health has developed over recent years in regard to...

5th Canadian Symposium on Hepatitis C Virus: "We're not done yet: Remaining Challenges in HCV"

2015/16 • $10,000 • PI,CO
Hepatitis C virus (HCV) affects over 268,000 Canadians and causes more years of life lost than any other infectious disease in the country. The CIHR and the Public Health Agency of Canada (PHAC) have identified liver disease due to HCV as a major public health problem. In 2015, new interferon...

National CIHR Research Training Program in Hepatitis C- Subvention nationale de formation des IRSC en hépatite C

2010/11-2014/15 • $1,630,000 • PI,CO
Hepatitis C infection remains a serious health problem both worldwide and in Canada. It is estimated that over 250 000 Canadians are chronically infected and over 6000 new cases occur each year. The annual death rate in Canada from Hepatitis C is 4700. Moreover, at least 15% of HIV-infected...

The complex dynamics of Hepatitis C virus and HIV infections among injection drug users: A comprehensive approach.

2010/11-2014/15 • $1,550,780 • PI,CO
Injection drug use accounts for the majority of new cases of Hepatitis C virus (HCV) infections and for 30% of all new cases of AIDS in Canada. Despite considerable prevention efforts, HIV incidence in Montreal injection drug users (IDUs) remains among the highest for North American cities, and...

Équipe des IRSC en Comorbidité des troubles cérébraux et autres problèmes de santé : Recherche sur le développement d'approches novatrices de prévention du VIH et du VHC chez les usagers de cocaïne souffrant de problèmes de santé mentale

2010/11-2014/15 • $1,337,823 • PI,CO
La concomitance sante mentale et consommation problematique de cocaine est rarement consideree dans les etudes sur les risques d'infection et dans l'offre de service en prevention du VIH et de l'hepatite C. Or, plusieurs etudes montrent que la consommation problematique de cocaine est associee...

Role of DCs and CD4+ T cells in acute HCV and HCV-related liver fibrosis

2011/12-2014/15 • $408,669 • PI,CO
Hepatitis C virus (HCV) infection usually causes a life-long persistent infection in humans that can lead to irreversible liver damage and even cancer. End-stage liver disease caused by HCV infection is the main cause of liver transplantation and liver cancer in North America. There is no...

Cross sectional and longitudinal measures of quality of life and utility among patients with chronic hepatitis C virus infection

2014/15 • $100,000 • PI,CO
There are 70,000 patients with chronic hepatitis C (CHC) infection in Canada who have not been treated, even though effective treatment is available. In this study, we plan to measure the quality of life and economic burden of CHC infection. The quality of life of HCV patients is poorly...

Fourth Canadian Symposium on Hepatitis C Virus

2014/15 • $10,000 • PI,CO
Hepatitis C virus (HCV) affects over 240,000 Canadians and causes more years of life lost than any other infectious disease in the country. The CIHR and the Public Health Agency of Canada (PHAC) have identified liver disease due to HCV as a major public health problem. In 2011 and 2013, new...

Study to Assess Longer-term Opioid Medication Effectiveness (SALOME): Multi-centre, double blind Randomized Controlled Trial comparing the efficacy of Diacetylmorphine vs. Hydromorphone for the treatment of long-term Injection Opiate Users who do not benefit from available therapies

2010/11-2013/14 • $998,077 • PI,CO
Inner city populations, particularly injection drug users, are at extremely high risk of many drug related harms including HIV, hepatitis C and overdose death. While some treatments exist, they are not optimal and people with the most severe cases of heroin addiction remain outside of the health...

Signatures of a Successful Immune Response against HCV

2010/11-2013/14 • $420,526 • PI,CO
Hepatitis C virus (HCV) infection usually causes a life-long persistent infection in humans that can lead to irreversible liver damage and even cancer. It is estimated that the number of persons currently infected with HCV in the world is approximately 130 million individuals. There is no...

CRISM-QUÉBEC: Réseau Québécois -Recherche sur les interventions en abus de substances/Research on Interventions for substance misuse

2013/14 • $49,832 • PI,CO,Other
Substance misuse remains a significant global public health problem which carries a heavy burden for abusers and their families alike. This disorder is associated with suffering and severe health problems in patients, distress among family members, as well as tremendous costs to society....

Third Canadian Symposium on Hepatitis C Virus

2013/14 • $25,000 • PI,CO
Hepatitis C virus (HCV) affects at least 240,000 people in Canada and causes more years of life lost than any infectious disease in the country. The CIHR and the Public Health Agency of Canada (PHAC) have identified liver disease due to HCV as a major public health problem. Understanding how to...

The impact of acute hepatitis C and antiviral treatment among active injection drug users

2010/11-2012/13 • $177,664 • PI,CO
One hundred and twenty-three million people world-wide are infected with hepatitis C virus (HCV). In Canada, 240,000 persons are living with HCV, and 63% of the estimated 8,000 yearly new HCV infections occur among injection drug users (IDUs). Spontaneous resolution of HCV infection is uncommon,...

Expanding HIV care models to meet the challenge of multi-morbidities in vulnerable populations

2011/12 • $25,000 • PI,CO
Tremendous advances have made in the treatment of HIV/AIDS rendering it a manageable chronic condition. As HIV-infected persons now survive for decades after acquiring their infection, co-morbid conditions increasingly impact health care access, clinical outcomes and costs. Important...

Canadian Symposium on Hepatitis C Virus

2011/12 • $19,920 • PI,CO
Hepatitis C virus (HCV) infects 170 million individuals worldwide. In Canada, approximately 240,000 are infected with an estimated 4,000 new infections each year. The majority of HCV exposed individuals develop a life-long persistent infection that can lead to irreversible liver damage and even...

Signatures of a Successful Immune Response against HCV

2010/11 • $100,000 • PI,CO
Hepatitis C virus (HCV) infection usually causes a life-long persistent infection in humans that can lead to irreversible liver damage and even cancer. It is estimated that the number of persons currently infected with HCV in the world is approximately 130 million individuals. There is no...

Brevets